Young-adulthood insulin resistance predicts later atherosclerotic cardiovascular disease, according to a CARDIA cohort analysis published in JACC: Advances, as MedPage Today reported.
Researchers tracked more than 3,000 participants who remained under observation and free of atherosclerotic cardiovascular disease through year 20, when they were 38 to 50 years old. At baseline, when individuals were between 18 and 30 years old, 25% of participants exhibited insulin resistance, as noted by investigators led by Chuyue Wu, MD, PhD, representing the UCLA Fielding School of Public Health in Los Angeles.
With repeated clinical assessments and long-term follow-up, individuals with insulin resistance in early adulthood faced a significantly higher risk of cardiovascular events through year 35 of the study, when they were 53 to 65 years old, yielding a risk ratio of 1.50 with a 95% confidence interval of 1.13 to 2.01, MedPage Today reported.
“These findings have potential implications for early cardiovascular prevention by suggesting that IR in young adulthood may signal an adverse CKM trajectory before conventional cardiometabolic risk factors become fully established,” Wu and colleagues wrote.
In Plain English: The Clinical Takeaway
- HOMA-IR Measurement: Insulin resistance was estimated using a Homeostatic Model Assessment of Insulin Resistance value at or above the 75th percentile following a 12-hour fast, serving as an indirect indicator instead of the gold-standard hyperinsulinemic-euglycemic clamp.
- Cardiovascular Risk Trajectory: Early metabolic dysfunction acts as an upstream warning sign for future heart disease, preceding the formal diagnosis of metabolic syndrome.
- Midlife Mediation: An estimated two-thirds of the association between early insulin resistance and later heart disease operated through the clustering of risk factors in middle age.
Cardiometabolic Risk and Midlife Metabolic Syndrome
Researchers found that 63.4% of the relationship between early insulin resistance and later cardiovascular events was mediated by midlife metabolic syndrome at the year-20 mark, generating an indirect risk ratio of 1.29, MedPage Today reported.
A person was diagnosed with metabolic syndrome by meeting three specific criteria, which include waist circumference of 102 cm or more in men and 88 cm or more in women, triglycerides of 150 mg/dL or higher, and specific high-density lipoprotein thresholds.
“The substantial mediation through midlife MetS further identifies the clustering of abnormalities in adiposity, blood pressure, glucose, and lipids as a potentially important intermediate stage linking early IR to later ASCVD,” Wu’s group suggested.
| Study Metric | Participant Age Range | Observed Risk Statistic |
|---|---|---|
| Baseline Enrollment | 18–30 years old | 25% exhibited high HOMA-IR (≥2.67) |
| Midlife Follow-Up | 38–50 years old (Year 20) | 63.4% mediation via metabolic syndrome |
| Late Follow-Up | 53–65 years old (Year 35) | RR 1.50 for ASCVD events |
Fasting insulin is not routinely measured in standard clinical practice, and study authors acknowledged they did not account for shifts in metabolic syndrome status prior to year 20. Residual confounding also remains possible given the observational design of the prospective cohort study, which originally enrolled 3,622 participants in 1985 and 1986 with a baseline mean age of 25.0 years, where 45% were men and 47% were Black.
That perspective was highlighted in a related commentary cowritten by Leonardo Roever, MHS, PhD, affiliated with the Brazilian Evidence-Based Health Network in Uberlândia, Brazil, alongside Amier Haidar, MD, MPH, of McGovern Medical School at the University of Texas Health Science Center at Houston.
“A young adult with progressively increasing abdominal adiposity, worsening blood pressure, rising triglycerides, and deteriorating glycemic measures should not need to accumulate multiple abnormalities before clinicians recognize the direction of travel,” Haidar and Roever stressed.
Contraindications & When to Consult a Doctor
Further research is required to determine whether calculating HOMA-IR improves risk prediction beyond standard clinical factors, to develop practical screening methods when fasting insulin is unavailable, and to test whether preventing progression to metabolic syndrome alters long-term cardiovascular outcomes.
“Young adulthood represents a particularly important and underused window for prevention,” Haidar and Roever asserted.
The UCLA Fielding School of Public Health was established on March 17, 1961, with Lenor S. Goerke as its first dean, evolving from public health instruction that began at UCLA in 1946.
In 2012, a $50 million gift from the Fielding family — the largest single donation in the school’s history — led to its renaming as the Jonathan and Karin Fielding School of Public Health. Today the school operates five academic departments, including Epidemiology and Biostatistics, and maintains 19 memoranda of understanding with institutions in countries such as Cambodia, China, Germany, and Mexico.
References
- Wu, C., et al. (2026). Young-Adulthood Insulin Resistance and Later-Life ASCVD Risk in the CARDIA Cohort. JACC: Advances.
- Editorial: Insulin Resistance and the Cardiovascular-Kidney-Metabolic Trajectory. JACC: Advances.
Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.